|
Assessment of Serum Ferritin Level in Thalassemia Major Patients Receiving Deferasirox in Comparison with Other Iron Chelators
|
F. Madani    , R. Taghvaee , H. Akbari |
|
|
| Keywords: Key words: Deferasirox, Thalassemia, Ferritin |
|
|
Full-Text [PDF 339 kb]
(366 Downloads)
| Abstract (HTML) (676 Views)
|
Type of Study: Research |
Subject:
Hematology and Oncology
Published: 2022/10/2
|
|
|
|
|
|
|
Full-Text: (1043 Views) |
References:
- Cappellini MD, Porter JB, Viprakasit V, Taher AT. A paradigm shifts on beta-thalassemia treatment: How will we manage this old disease with new therapies. Blood Rev 2018; 32(4): 300-11.
- Hill QA, Hill A, Berentsen S. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Adv 2019; 3(12): 1897-906
- Hajigholami A, Ansari H, Honarmand S. Comparing the efficacy of Dexeroyx (Osveral) and Deferoxamine (Desferal) in reducing serum ferritin level in patients with thalassemia major. Middle East J Fam Med 2018; 7(10): 218-22.
- Mobarra N, Shanaki M, Ehteram H, Nasiri H, Sahmani M, Saeidi M, et al. A Review on Iron Chelators in Treatment of Iron Overload Syndromes. Int J Hematol Oncol Stem Cell Res 2016; 10: 239-47.
- Kontoghiorghes GJ, Kleanthous M, Kontoghiorghe CN. The history of deferiprone (L1) and the paradigm of the complete treatment of iron overload in thalassaemia. Mediterr J Hematol Infect Dis 2019; 12(1): e2020011.
- Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: a clinical review. Clin Ther 2007; 29(10): 2154-66.
- Tinsley SM, Hoehner-Cooper CM. Transitioning Patients with Iron Overload from Exjade to Jadenu. J Infus Nurs 2018; 41(3): 171-5.
- Quarta A, Sgherza N, Pasanisi A, Solfrizzi MP, Serra M, Vitucci A, et al. Switching from dispersible to film coated tablet formulation of deferasirox improves hemoglobin levels and transfusional interval in patients with transfusion-dependent-thalassemia. Br J Haematol 2020; 189(2): e60-e3.
- Moradveisi B, Taghizadeh Sarvestani R, Ghaderi E, Kompany F. Comparison of the heart and liver iron deposition status in Major β Thalassemia patients treated with two iron chelation drugs of Deferoxamine and Deferasiroxon using MRI T2 technique. Sci J Iran Blood Transfus Organ 2015; 12(1): 55-62. [Article in Farsi]
- Emamgholipour S, Ahmadi B, Rajabi A, Azarkeivan A, Ebrahimi M, Esmaeilzadeh F. Cost-utility of treatment of the patients with Thalassemia Major in Iran. Sci J Iran Blood Transfus Organ. 2018; 15(4): 257-64. [Article in Farsi]
- Chalmers AW, Shammo JM. Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. Ther Clin
Risk Manag 2016; 12: 201-8.
- Hassan MA, Tolba OA. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electron Physician 2016; 8(5): 2425-31.
- Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, et al. CORDELIA study investigators. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood 2014; 123(10): 1447-54.
- Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, et al. Efficacy and safety of deferasirox doses of > 30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009; 147(5): 752-9.
- Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelators deferasirox/ deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Eur J Haematol 2015; 95(5): 411-20.
- Dou H, Qin Y, Chen G, Yanjun Zhao. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis. Acta Haematol 2019; 141: 32-42.
- Shukla SK. Effect of deferasirox on serum ferritin level in children with thalassemia major: impact of transfusional iron load. Int J Contemp Pediatr 2019; 6(5): 2081-6.
- Saiyarsarai P, Khorasani E. Cost-utility of new film-coated tablet formulation of deferasirox vs deferoxamine among major beta-thalassemia patients in Iran. Medicine 2020; 99(28): e20949.
- Tinsley S , Hoehner-Cooper C. Transitioning Patients With Iron Overload From Exjade to Jadenu. J Infus Nurs 2020; 41(3): 171-5.
- Ashayeri N, Sadeghi E, Sadeghi S, Eshghi P, Alavi S. Efficacy of Deferasirox (Exjade®) versus Osveral® in Treatment of Iron Overload in Patients with Beta- thalassemia Major in Iran; A Non-randomized Controlled Trial. Iran J Blood Cancer 2016; 8(4): 103-7.
- Arya A, Jokar S, Etemadfar P. Comparison of Deferoxamine, Deferiprone and Deferasirox Iron-Chelating Agents in Reducing Serum Ferritin Levels in Patients with Thalassemia Major. J Clin Care Skill 2020; 1(4): 189-93.
|
Sci J Iran Blood Transfus Organ 2022;19 (3): 200-207
|
Assessment of Serum Ferritin Level in Thalassemia Major Patients Receiving Deferasirox in Comparison
with Other Iron Chelators
Madani F.1, Taghvaee R.1, Akbari H.2
1School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
2School of Health, Kashan University of Medical Sciences, Kashan, Iran
Abstract
Background and Objectives
Although blood transfusion is the most important method to control thalassemia major, this method leads to the iron accumulation in various tissues and organs of patients. The aim of this study was to compare the effect of Deferasirox with new formulations and other iron chelator drugs on serum ferritin level and gastrointestinal effects in thalassemia major patients in thalassemia center of Kashan University of Medical Sciences during a two-year period.
Materials and Methods
This semi-experimental study was performed on 45 thalassemia patients. In 2018, these patients were treated with a drug other than Defrasirox with a new formulation. In 2018, all patients were treated with the new Defrasirox. Serum ferritin level was measured once every three months, compared with the previous year, and analyzed by Kolmogorov smirnov, Anova and SPSS 19.
Results
In 2018 and 2019, there was no significant difference in terms of serum ferritin level. In 2019, with the use of the new drug Deferasirox, a total of 11.1% of patients have suffered from complications of drug use, which is a significant decrease compared to the previous year (p = 0.004).
Conclusions
The effect of the Deferasirox with new formulation in reducing serum ferritin level in patients with thalassemia major is similar to previous drugs (old Deferasirox, deferiprone and desferrioxamine). However, patients recieving this drug have less gastrointestinal effects such as pain, nausea, vomiting and diarrhea. At the same time, the satisfaction with the drug has increased significantly.
Key words: Deferasirox, Thalassemia, Ferritin
Received: 5 Jan 2022
Accepted: 20 Apr 2022
Correspondence: Taghvaee R., Pediatric Assistant. School of Medicine, Kashan University of Medical Sciences.
Postal Code: 8715973474, Kashan, Iran. Tel: (+9831) 55443022; Fax: (+9831) 55464950
E-mail: taghvaee68@gmail.com
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Madani F, Taghvaee R, Akbari H. Assessment of Serum Ferritin Level in Thalassemia Major Patients Receiving Deferasirox in Comparison with Other Iron Chelators. Sci J Iran Blood Transfus Organ 2022; 19 (3) :200-207 URL: http://bloodjournal.ir/article-1-1440-en.html
|
.jpg)
.png)
